These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22431852)

  • 1. In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans.
    Ambrose PG; Drusano GL; Craig WA
    Clin Infect Dis; 2012 Apr; 54 Suppl 3():S220-8. PubMed ID: 22431852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oritavancin: a new avenue for resistant Gram-positive bacteria.
    Mercier RC; Hrebickova L
    Expert Rev Anti Infect Ther; 2005 Jun; 3(3):325-32. PubMed ID: 15954849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
    McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
    J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.
    Crandon J; Nicolau DP
    Future Microbiol; 2008 Jun; 3(3):251-63. PubMed ID: 18505390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.
    Poulakou G; Giamarellou H
    Expert Opin Investig Drugs; 2008 Feb; 17(2):225-43. PubMed ID: 18230056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oritavancin: a novel lipoglycopeptide active against Gram-positive pathogens including multiresistant strains.
    Bouza E; Burillo A
    Int J Antimicrob Agents; 2010 Nov; 36(5):401-7. PubMed ID: 20729040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens.
    Das B; Sarkar C; Schachter J
    Pak J Pharm Sci; 2013 Sep; 26(5):1045-55. PubMed ID: 24035967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.
    Corey GR; Arhin FF; Wikler MA; Sahm DF; Kreiswirth BN; Mediavilla JR; Good S; Fiset C; Jiang H; Moeck G; Kabler H; Green S; O'Riordan W;
    Int J Antimicrob Agents; 2016 Nov; 48(5):528-534. PubMed ID: 27665522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo antibacterial activity and pharmacological properties of the membrane-active glycopeptide antibiotic YV11455.
    Yarlagadda V; Konai MM; Manjunath GB; Prakash RG; Mani B; Paramanandham K; Ranjan SB; Ravikumar R; Chakraborty SP; Roy S; Haldar J
    Int J Antimicrob Agents; 2015 Jun; 45(6):627-34. PubMed ID: 25900818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oritavancin: a long-acting antibacterial lipoglycopeptide.
    Kaasch AJ; Seifert H
    Future Microbiol; 2016 Jul; 11():843-55. PubMed ID: 27161039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oritavancin: A Long-Half-Life Lipoglycopeptide.
    Saravolatz LD; Stein GE
    Clin Infect Dis; 2015 Aug; 61(4):627-32. PubMed ID: 25900171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycopeptides in clinical development: pharmacological profile and clinical perspectives.
    Van Bambeke F
    Curr Opin Pharmacol; 2004 Oct; 4(5):471-8. PubMed ID: 15351351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015.
    Karlowsky JA; Walkty AJ; Baxter MR; Arhin FF; Moeck G; Adam HJ; Zhanel GG
    Diagn Microbiol Infect Dis; 2017 Apr; 87(4):349-356. PubMed ID: 28159446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.
    Corey GR; Good S; Jiang H; Moeck G; Wikler M; Green S; Manos P; Keech R; Singh R; Heller B; Bubnova N; O'Riordan W;
    Clin Infect Dis; 2015 Jan; 60(2):254-62. PubMed ID: 25294250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-dose oritavancin in the treatment of acute bacterial skin infections.
    Corey GR; Kabler H; Mehra P; Gupta S; Overcash JS; Porwal A; Giordano P; Lucasti C; Perez A; Good S; Jiang H; Moeck G; O'Riordan W;
    N Engl J Med; 2014 Jun; 370(23):2180-90. PubMed ID: 24897083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.
    Roberts KD; Sulaiman RM; Rybak MJ
    Pharmacotherapy; 2015 Oct; 35(10):935-48. PubMed ID: 26497480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oritavancin: a new opportunity for outpatient therapy of serious infections.
    Tice A
    Clin Infect Dis; 2012 Apr; 54 Suppl 3():S239-43. PubMed ID: 22431855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci.
    Napolitano LM
    Surg Infect (Larchmt); 2005; 6 Suppl 2():S-5-22. PubMed ID: 23577494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy.
    Van Bambeke F
    Curr Opin Investig Drugs; 2006 Aug; 7(8):740-9. PubMed ID: 16955686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.